Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

BeiGene Shares Updated Data From Tislelizumab Combo Trial In Head & Neck Cancer

  • BeiGene Ltd (NASDAQ:BGNEshared updated data analyses from the Phase 3 RATIONALE-309 trial of tislelizumab combined with chemotherapy versus chemotherapy plus placebo in first-line recurrent or metastatic nasopharyngeal cancer.
  • Updated efficacy analyses showed that, at a median follow-up of 15.5 months, tislelizumab/chemotherapy combo demonstrated a clinically significant progression-free survival (PFS) benefit over chemotherapy alone. 
  • The safety profile of the tislelizumab and chemotherapy combination was generally manageable and consistent with the known risks of each treatment agent.
  • Read Next: BeiGene's Brukinsa Tops JNJ's Imbruvica In Overall Response Rate In Leukemia Study.
  • Patients administered a 200 mg dose of tislelizumab + chemo achieved a median PFS of 9.6 months compared to 7.4 months for placebo control + chemotherapy patients.
  • For patients treated with tislelizumab plus chemotherapy, median PFS2 was not yet reached compared to 13.9 months for those treated with placebo plus chemotherapy. 
  • A positive overall survival (OS) trend was also observed with median OS not yet reached in the tislelizumab combination arm and 23 months for the chemotherapy plus placebo arm.
  • Price Action: BGNE shares are up 0.94% at $173.77 during the market session on the last check Tuesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.